Question 1

What specific side effects should I be aware of when taking palbociclib or ribociclib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients? clinical trial (NCT05051956). Contact the study team or your healthcare provider for specific answers.

Question 2

How will the questionnaires help in predicting side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients? clinical trial (NCT05051956). Contact the study team or your healthcare provider for specific answers.

Question 3

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients? clinical trial (NCT05051956). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any other treatment options I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients? clinical trial (NCT05051956). Contact the study team or your healthcare provider for specific answers.

Question 5

How often will I need to visit the clinic during this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients? clinical trial (NCT05051956). Contact the study team or your healthcare provider for specific answers.

What this study is about